Oppenheimer Holdings Stock News

Big misses with guidance lead to a clutch of analyst price-target cuts, and even a pair of downgrades.

REDWOOD CITY, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that it is scheduled to participate in a fireside chat at the Oppenheimer 32 nd Annual Virtual Healthcare Conference on Wednesday, March 16, 2022 at 7:00am Pacific Time. Thomas Butler, Biomea’s CEO and Chairman of the Board, will participate in the fireside chat.

Montrouge, France, March 14, 2022 DBV Technologies to Present at the Oppenheimer''s 32nd Annual Healthcare Conference DBV Technologies (GREY: DBVTF ), a clinical-stage biopharmaceutical company, today announced that Dr. Pharis Mohideen, Chief Medical Officer, will present at the Oppenheimer''s 32nd Annual Healthcare Conference on Thursday, March 17 th at 10:00 a.m. ET. A webcast of the presentation may be accessed by visiting the Investors & Media section of the DBV Technologies website at https://www.dbvtechnologies.com/investor-relations/ . An archived replay of the webcast … Full story available on Benzinga.com

Crypto exchange Coinbase’s stock is undervalued, the investment bank said in a note to clients.

Oppenheimer recommended that investors buy McDonald''s MCD on any further weakness with the same-store sales strength expected. Read more on MCD stock.

PALO ALTO, Calif. and SUZHOU, China, March 10, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the Oppenheimer 32 nd Annual Healthcare Conference from March 15 th to 17 th .

CAMBRIDGE, Mass., March 10, 2022 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that company management will present a corporate overview at Oppenheimer''s…

WARRINGTON, Pa., March 10, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and be available for 1x1 meetings at the Oppenheimer 32 nd Annual Healthcare Conference on Tuesday, March 15 at 1:20 p.m. Eastern Time. To view the presentation, click Full story available on Benzinga.com

EMERYVILLE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA ), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chairman and Chief Executive Officer, Jim Neal, will present at Oppenheimer''s 32 nd Annual Healthcare Conference (virtual) on Thursday, March 17, 2022, at 12:40 PM ET. The presentation can be accessed at https://bit.ly/3truAX8 or by visiting the investor relations section of the Company''s website at www.xoma.com . A replay of the presentation will be available and archived on the site for 90 days after … Full story available on Benzinga.com

EMERYVILLE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chairman and Chief Executive Officer, Jim Neal, will present at Oppenheimer’s 32 nd Annual Healthcare Conference (virtual) on Thursday, March 17, 2022, at 12:40 PM ET.

MELBOURNE, Australia, March 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Company''s Chief Executive Officer, will present at Oppenheimer''s 32nd Annual Healthcare Conference, being held virtually from March 15-17, 2022. The presentation will be available beginning Tuesday, March 15, at 8:40 am ET (11:40 pm AEDT), and may be accessed for 90 days on the Investors page of the Opthea website at https://www.opthea.com/presentations/ . About Opthea Limited Opthea ((ASX:OPT, NASDAQ: OPT ) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea''s lead product candidate OPT-302 … Full story available on Benzinga.com

Immunocore to present at Oppenheimer’s 32 nd Annual Healthcare Conference

Immunocore to present at Oppenheimer''s 32 nd Annual Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 March 2022) Immunocore Holdings Plc (NASDAQ: IMCR ), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announced that management will participate in a fireside chat at the Oppenheimer 32 nd Annual Healthcare Conference. The presentation is scheduled for Wednesday, March 16, 2022 at 9:20 a.m. Eastern Time (ET). The presentation will be webcast live during the conference and will be available in the ‘Investors'' section of Immunocore''s website at www.immunocore.com . A replay of the presentation will be made available for a limited time. ## About Immunocore Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease.

Emerson <> edges higher as Oppenheimer upgrades shares to Outperform from Market Perform with a $110 price target, citing "excellent persistent capital preservation characteristics…